{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000006","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.619731+00:00","generated_at":"2026-06-07T00:52:08.227692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Globus Medical reports record Q4 sales $615.5M (+124% YoY); FY2024 guidance $2.45-2.475B","bullets":["Q4 2023 sales ~$615.5M, up 124.2% as-reported, including NuVasive merger impact.","Full year 2023 sales ~$1.567B, up 53.2% as-reported over prior year.","Legacy Globus Q4 revenue $302.9M (+10.4% YoY); full year $1.152B (+12.7%).","FY2024 revenue guidance $2.450-2.475B; non-GAAP EPS guidance $2.68-$2.70.","Completed NuVasive merger Sept 1, 2023; integration on track with strong sales retention."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000006","json":"https://secwatch.observer/filing/0001562762-24-000006.json","markdown":"https://secwatch.observer/filing/0001562762-24-000006.md","text":"https://secwatch.observer/filing/0001562762-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/0001562762-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/gmed-20240110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:52:08.227692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b464ed40ecaf9746d777e3b37c5a491f4df05578","claim":"GLOBUS MEDICAL INC updated its the three-month period and fiscal year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"On January 10, 2024, we issued a press release reporting our preliminary unaudited net sales results for the three-month period and fiscal year ended December 31, 2023. The press release also included preliminary guidance for certain financial measures for the 2024 fiscal year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276224000006/0001562762-24-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three-month period and fiscal year ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}